Indaptus Therapeutics (INDP) Short Interest Ratio & Short Volume $0.59 -0.06 (-9.23%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.60 +0.01 (+1.19%) As of 03/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Indaptus Therapeutics Short Interest DataIndaptus Therapeutics (INDP) has a short interest of 52,400 shares, representing 0.45% of the float (the number of shares available for trading by the public). This marks a -9.97% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 139,483 shares to cover all short positions.Current Short Interest52,400 sharesPrevious Short Interest58,200 sharesChange Vs. Previous Month-9.97%Dollar Volume Sold Short$42,187.24Short Interest Ratio0.1 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares14,429,000 sharesFloat Size11,610,000 sharesShort Percent of Float0.45%Today's Trading Volume178,719 sharesAverage Trading Volume139,483 sharesToday's Volume Vs. Average128% Short Selling Indaptus Therapeutics? Sign up to receive the latest short interest report for Indaptus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINDP Short Interest Over TimeINDP Days to Cover Over TimeINDP Percentage of Float Shorted Over Time Remove Ads Indaptus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202552,400 shares $42,187.24 -10.0%0.5%0.1 $0.81 2/28/202558,200 shares $48,829.80 -25.9%0.5%2.5 $0.84 2/15/202578,500 shares $62,721.50 +102.8%0.7%3.1 $0.80 1/31/202538,700 shares $35,217.00 -41.7%0.4%1.6 $0.91 1/15/202566,400 shares $57,768.00 -11.2%0.7%0.6 $0.87 12/31/202474,800 shares $62,989.08 -19.1%0.8%0.7 $0.84 12/15/202492,500 shares $92,500.00 +0.5%1.0%0.8 $1.00 11/30/202492,000 shares $93,840.00 +8.2%1.1%0.8 $1.02 11/15/202485,000 shares $94,350.00 -38.7%1.1%0.8 $1.11 10/31/2024138,700 shares $162,279.00 +348.9%1.9%1.3 $1.17 Get the Latest News and Ratings for INDP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202430,900 shares $39,243.00 -9.7%0.4%0.3 $1.27 9/30/202434,200 shares $42,408.00 +284.3%0.5%2.5 $1.24 9/15/20248,900 shares $13,439.00 +140.5%0.1%0.7 $1.51 8/31/20243,700 shares $6,095.38 -47.9%0.1%0.3 $1.65 8/15/20247,100 shares $11,857.00 -12.4%0.1%0.4 $1.67 7/31/20248,100 shares $16,519.95 -42.6%0.1%0.4 $2.04 7/15/202414,100 shares $31,020.00 +147.4%0.2%0.7 $2.20 6/30/20245,700 shares $12,084.00 +9.6%0.1%0.2 $2.12 6/15/20245,200 shares $12,844.00 -66.7%0.1%0.2 $2.47 5/31/202415,600 shares $36,972.00 -6.0%0.3%0.5 $2.37 5/15/202416,600 shares $36,686.00 -35.7%0.3%0.2 $2.21 4/30/202425,800 shares $55,986.00 -70.1%0.4%0.3 $2.17 4/15/202486,200 shares $228,430.00 -13.9%1.5%1 $2.65 3/31/2024100,100 shares $224,224.00 +0.7%1.7%1.3 $2.24 3/15/202499,400 shares $185,878.00 +196.7%1.7%1.3 $1.87 2/29/202433,500 shares $73,700.00 +94.8%0.6%0.5 $2.20 2/15/202417,200 shares $29,928.00 +18.6%0.3%1.8 $1.74 1/31/202414,500 shares $23,925.00 -20.8%0.3%1.5 $1.65 1/15/202418,300 shares $33,855.00 -10.7%0.3%1.3 $1.85 12/31/202320,500 shares $36,080.00 -9.3%0.4%1.5 $1.76 12/15/202322,600 shares $44,748.00 -2.6%0.4%1.7 $1.98 11/30/202323,200 shares $52,432.00 +21.5%0.4%1.4 $2.26 11/15/202319,100 shares $42,020.00 +64.7%0.3%1 $2.20 10/31/202311,600 shares $26,448.00 -3.3%0.2%0.5 $2.28 10/15/202312,000 shares $30,720.00 -14.3%0.2%0.6 $2.56 9/30/202314,000 shares $38,570.00 -31.7%0.2%0.7 $2.76 9/15/202320,500 shares $69,290.00 -9.3%0.4%1 $3.38 8/31/202322,600 shares $64,862.00 -51.6%0.4%1.3 $2.87 8/15/202346,700 shares $104,608.00 +115.2%0.8%2.8 $2.24 7/31/202321,700 shares $44,919.00 +29.9%0.4%1.6 $2.07Wall Street’s “AI Oracle” Reveals Next Big Tech Play (Ad)A tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Oracle"—known for spotting Apple, Amazon, and Google early—has identified a firm with patented tech that could become essential to every major AI player. He shares the name and ticker in this free video—but warns the opportunity could vanish once it hits the mainstream.Click here to watch the video before it goes viral. 7/15/202316,700 shares $31,730.00 -1.8%0.3%1.3 $1.90 6/30/202317,000 shares $32,470.00 -28.3%0.3%0.6 $1.91 6/15/202323,700 shares $46,452.00 -11.9%0.4%0.8 $1.96 5/31/202326,900 shares $43,847.00 -0.4%0.5%0.9 $1.63 5/15/202327,000 shares $56,160.00 -51.4%0.5%1 $2.08 4/30/202355,600 shares $145,060.40 +159.8%1.0%2 $2.61 4/15/202321,400 shares $41,730.00 -9.3%0.4%0.8 $1.95 3/31/202323,600 shares $43,660.00 -12.6%0.4%3.1 $1.85 3/15/202327,000 shares $41,040.00 +4.7%0.5%2.9 $1.52 2/28/202325,800 shares $45,150.00 -21.3%0.5%1 $1.75 2/15/202332,800 shares $58,712.00 -16.1%0.6%1.3 $1.79 1/31/202339,100 shares $69,207.00 +3.7%0.7%1.5 $1.77 1/15/202337,700 shares $61,451.00 -29.8%0.7%1.5 $1.63 12/30/202253,700 shares $77,865.00 -46.3%1.1%2.2 $1.45 12/15/2022100,000 shares $195,000.00 +498.8%2.0%4.2 $1.95 11/30/202216,700 shares $30,415.71 -4.6%0.3%1.6 $1.82 11/15/202217,500 shares $30,276.75 +5.4%0.4%1.6 $1.73 10/31/202216,600 shares $30,378.00 +9.2%0.3%1.4 $1.83 10/15/202215,200 shares $27,360.00 -14.6%0.3%1.1 $1.80 9/30/202217,800 shares $38,448.00 -21.9%0.4%1.1 $2.16 9/15/202222,800 shares $61,104.00 -8.1%0.5%0.9 $2.68 8/31/202224,800 shares $62,496.00 -31.7%0.5%0.7 $2.52 8/15/202236,300 shares $105,270.00 -36.9%0.7%0.6 $2.90 7/31/202257,500 shares $163,300.00 -25.3%1.1%0.1 $2.84 7/15/202277,000 shares $256,410.00 +49.8%1.5%0.2 $3.33 6/30/202251,400 shares $134,154.00 -42.6%1.0%0.1 $2.61 6/15/202289,500 shares $200,480.00 -50.9%1.6%0.2 $2.24 5/31/2022182,100 shares $460,713.00 +569.5%3.2%0.4 $2.53 5/15/202227,200 shares $67,456.00 -38.3%0.5%0.1 $2.48 4/30/202244,100 shares $129,213.00 -14.7%0.8%1 $2.93 4/15/202251,700 shares $177,331.00 -18.1%0.9%0.9 $3.43 3/31/202263,100 shares $252,400.00 -30.6%1.1%0.8 $4.00 3/15/202290,900 shares $289,971.00 +21.2%1.6%0.6 $3.19 2/28/202275,000 shares $313,500.00 +6.8%1.4%0.4 $4.18 2/15/202270,200 shares $351,000.00 -34.2%1.3%0.3 $5.00 1/31/2022106,600 shares $531,934.00 +2.8%1.9%0.4 $4.99 1/15/2022103,700 shares $547,536.00 +157.3%1.9%0.4 $5.28 12/31/202140,300 shares $229,710.00 No Change0.7%0.1 $5.70 INDP Short Interest - Frequently Asked Questions What is Indaptus Therapeutics' current short interest? Short interest is the volume of Indaptus Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 52,400 shares of INDP short. 0.45% of Indaptus Therapeutics' shares are currently sold short. Learn More on Indaptus Therapeutics' current short interest. What is a good short interest percentage for Indaptus Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.45% of Indaptus Therapeutics' floating shares are currently sold short. Is Indaptus Therapeutics' short interest increasing or decreasing? Indaptus Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 52,400 shares, a decrease of 10.0% from the previous total of 58,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Indaptus Therapeutics' float size? Indaptus Therapeutics currently has issued a total of 14,429,000 shares. Some of Indaptus Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Indaptus Therapeutics currently has a public float of 11,610,000 shares. How does Indaptus Therapeutics' short interest compare to its competitors? 0.45% of Indaptus Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Indaptus Therapeutics: bluebird bio, Inc. (19.19%), FibroGen, Inc. (5.04%), ALX Oncology Holdings Inc. (18.80%), Cadrenal Therapeutics, Inc. (4.05%), Tempest Therapeutics, Inc. (4.42%), Estrella Immunopharma, Inc. (0.22%), Reviva Pharmaceuticals Holdings, Inc. (11.70%), Exicure, Inc. (1.79%), NRx Pharmaceuticals, Inc. (7.34%), LAVA Therapeutics (1.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Indaptus Therapeutics stock? Short selling INDP is an investing strategy that aims to generate trading profit from Indaptus Therapeutics as its price is falling. INDP shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Indaptus Therapeutics? A short squeeze for Indaptus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of INDP, which in turn drives the price of the stock up even further. How often is Indaptus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INDP, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies BLUE Short Interest Data FGEN Short Interest Data ALXO Short Interest Data CVKD Short Interest Data TPST Short Interest Data ESLA Short Interest Data RVPH Short Interest Data XCUR Short Interest Data NRXP Short Interest Data LVTX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INDP) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
